Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024


◆タイトル:Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024
◆レポート形式:PDF / 英語
Sigle UserGBP3,499 ⇒換算¥524,850見積依頼/購入/質問フォーム
Departmental/Five UserGBP3,899 ⇒換算¥584,850見積依頼/購入/質問フォーム
Site LicenseGBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。



Epigenetics market – new analysis showing you technological trends and sales forecasts
Do you want to find sales potentials of epigenetic technologies, diagnostics and medicines? Now get the latest analysis for that industry. There you explore developments (R&D), results, opportunities, trends and revenue forecasts.

Visiongain’s updated report shows you what’s possible for those drugs, diagnostic tests and related technology. Avoid missing out in data. Instead find progress in that industry and market, discovering expected advances and sales rises. See now how you can gain.

Assess technologies, products and services, benefiting your reputation for technological, medical and commercial insight. Read on, then, to explore that market and see its potential.

Forecasts and other information showing technical, clinical and business prospects
That new study gives you sales predictions to 2024 at overall world market, submarket, product and national level. See what the future holds for that emerging industry. For epigenetics you investigate where demand, opportunity and money lie.

Epigenetic uses hold great potential for diagnosing and treating diseases, including cancer.

There hear what’s possible. And avoid struggles to find information. Besides giving revenue predictions, our analysis shows historical results, growth rates and market shares.

In that work you discover 72 tables, 57 charts and an interview. There help your research, analyses and decisions, also benefiting your influence and staying ahead.

And the following sections explain what our new investigation gives.

World market and its segments – what revenues possible from 2014 to 2024?
What’s the commercial potential of epigenetics? Find in our report overall world revenue to 2024 for those products and technologies.

Also find individual revenue predictions to 2024 for three epigenetic submarkets at world level:
• Therapies
• Technologies for research
• Diagnostics

What’re the secrets of progress? There you assess outlooks for trade expansion, hearing where you could benefit. That work investigates products, uses and rising sales. You find commercial prospects.

That study also predicts and discusses leading epigenetic medicines’ sales potentials.

Revenue predictions for leading drugs and expected therapies
Our study forecasts revenues of top brands – four leading agents and two therapies awaiting launch. There you see individual revenue forecasts to 2024 for these products:
• Vidaza
• Dacogen
• Zolinza
• Istodax

And you gain predictions for these expected treatments:
• Beleodaq
• Faridak

There you explore drugs and years with highest predicted sales. Also you examine competitors. You see what’s happening there, understanding, challenges, trends and outlooks.

For that overall market, the report also shows geographical revenue predictions.

Sales in leading national markets – what outlooks for epigenetics?
Advances in pharmaceuticals, biotechnology and healthcare expand use of epigenetic services and products. See their prospects in developed and developing regions.

Our analyses show you individual revenue forecasts to 2024 for eight national markets and two regions:
• United States (US)
• Japan
• Canada
• Germany, France, UK, Italy and Spain (EU5), also with EU regional prediction
• Brazil, Russia, India and China (BRIC nations, grouped analysis).

There you find countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain. The study explains, helping you stay ahead.

Also how do events, challenges and advances in technology affect that industry and market? Our work shows you, discussing progress, policies and trends.

Strengths, challenges and events – what affects epigenetics?
The report explains issues, events and research and development (R&D) affecting that industry and market from 2014, including these forces:
• Uses for epigenetics in cancer, inherited disorders and neurological diseases
• DNA methlytransferase (DNMT) inhibition
• Histone deacetylase (HDAC) inhibitors
• Drug discovery and development using epigenetics
• Bisulphite screening for DNA methylation.

And you explore these influences and opportunities, among others:
• Chromatin immunoprecipitation (ChIP) for histone modification
• Chemogenic approaches to spatiotemporal regulation of HDAC activity
• Lysine pathways and acetylation-independent mechanisms
• DNMT inhibition and targeting other epigenetic enzymes
• Applications of genomics, proteomics and metabolomics
• Targeting orphan diseases and subpopulations – personalised and stratified medicine.

You explore what progress, trends and prospects mean. And you discover what benefits and restrains companies, affecting commercial performance. So what does the future hold?

Epigenetics – leading companies and 2018 market value
From 2014, applications of epigenetics hold great potential for investments, technological advances and sales. What happens next?

Our new report predicts the world market for those products and technologies will reach $4,279m in 2018, with high further sales growth to 2024.

There you also see what organisations shape that industry:
• Celgene
• Eisai
• Roche
• Janssen-Cilag
• Otsuka Pharmaceuticals
• Merck & Co.

You also assess activities of these firms:
• TopoTarget
• Syndax Pharmaceuticals
• MDxHealth
• Epigenomics
• Life Technologies
• Qiagen, 4SC, EMD Millipore, Orion Genomics, DiscoveRx, EpiTherapeutics and others.

R&D in that industry holds strengths. And from 2014 there will arise many opportunities. From this decade onwards, patients, payers and companies will benefit. See how.


1. Report Overview
1.1 Epigenetic Therapies, Technologies and Diagnostics: World Market Review
1.2 Global Epigenetics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Introduction to Epigenetics and Uses in Pharma
2.1 How is Epigenetics Defined?
2.1.1 Epigenetic Mechanisms
2.1.2 A Brief History of Epigenetic Research
2.2 The Links between Epigenetics and Disease
2.2.1 The Role of Lifestyle in Epigenetics
2.2.2 Epigenetics and Cancer
2.2.3 Epigenetics in Inherited Disorders
2.2.4 Epigenetics in Neurological Diseases
2.3 Epigenetics in Disease Diagnosis
2.3.1 Diagnosing for Breast Cancer
2.3.2 Colorectal Cancer: The Importance of Early Diagnosis
2.3.3 Diagnostics for Lung Cancer: Difficulty in Accessing Samples
2.3.4 Diagnostics for Prostate Cancer
2.4 The Use of Epigenetics in Treating Diseases
2.4.1 DNA Methlytransferase (DNMT) Inhibitors Myelodysplastic Syndrome (MDS)
2.4.2 Histone Deacetylase (HDAC) Inhibitors Cutaneous T Cell Lymphoma (CTCL) Peripheral T Cell Lymphoma (PTCL)
2.5 Drug Discovery and Development Tools Using Epigenetics
2.5.1 Bisulphite Screening for DNA Methylation
2.5.2 Chromatin Immunoprecipitation (ChIP) for Histone Modification

3. The Global Epigenetic Therapies, Technologies and Diagnostics Market 2014-2024
3.1 The Global Epigenetic Therapies, Technologies and Diagnostics Market in 2013
3.1.1 Leading Segments of the Market in 2013
3.2 The Epigenetic Therapies, Technologies and Diagnostics Global Market 2014-2024
3.2.1 The Epigenetic Therapies, Technologies and Diagnostics Global Market: Revenue Forecasts 2014-2024
3.2.2 What Will Expedite the Growth of Epigenetic Therapies, Technologies and Diagnostics Market?
3.2.3 Increase in Epigenetic Diagnostics Market Share 2014-2024
3.3 Epigenetic Therapies Submarket 2014-2024
3.3.1 Epigenetic Therapies Submarket: Revenue Forecast 2014-2024
3.3.2 Rising Importance of Epigenetic Therapies Revenue 2014-2024
3.4 Epigenetic Technologies Submarket 2014-2024
3.4.1 Epigenetic Technologies Submarket: Revenue Forecast 2014-2024
3.4.2 Epigenetic Technologies Submarket: Drivers and Restraints 2014-2024
3.5 Epigenetic Diagnostics Submarket 2014-2024
3.5.1 Epigenetic Diagnostics Submarket: Revenue Forecast 2014-2024
3.5.2 Growth Driving Factor: New Product Launches 2014-2024

4. Leading National Epigenetic Therapies, Technologies and Diagnostics Markets 2014-2024
4.1 Leading National Markets for Epigenetic Therapies, Technologies and Diagnostics 2013
4.2 Leading National Markets: Revenue Forecasts 2014-2024
4.2.1 Global Market Will Be Dominated by the Western Countries 2014-2024
4.3 The Northern American Market 2014-2024
4.3.1 The US: The World’s Largest Market for the Epigenetic Therapies, Technologies and Diagnostics 2014-2024
4.3.2 Canada: Revenue Forecast 2014-2024
4.4 European Union (EU) Epigenetics Market: Revenues 2013
4.4.1 Leading National Markets in EU: Revenue Forecasts 2014-2024
4.4.2 Germany: Revenue Forecast 2014-2024
4.4.3 The UK: A Leading Country for Epigenetic Research
4.5 Japanese Market: Increased Interest in Epigenetics
4.6 Epigenetics in Emerging National Markets
4.6.1 BRIC Nations: Positive Growth Expected in Epigenetic Therapies, Technologies and Diagnostics Markets 2014-2024

5. Epigenetic Therapies Market 2014-2024
5.1 The Future of the Epigenetic Therapies Market 2014-2024
5.2 Vidaza (Celgene Co. / Nippon Shinyaku): The First Therapy in the Epigenetic Market
5.2.1 Vidaza: Leading Epigenetic Therapy 2004-2012
5.2.2 How Was Vidaza Affected by Patent Expiry?
5.2.3 Will Oral Azacitidine and Combination Therapy Stimulate Vidaza Growth?
5.2.4 Vidaza: Revenue Forecast 2014-2024
5.3 Dacogen (Eisai/ Janssen-Cilag/ Otsuka Pharmaceutical Co.)
5.3.1 Dacogen: Historical Revenue Performance 2006-2012
5.3.2 EU Approval and Combination Therapy to Drive Sales Growth?
5.3.3 Will Oral Azacitidine and Combination Therapy Drive Vidaza Growth?
5.3.4 Dacogen: Revenue Forecast 2014-2024
5.4 Zolinza (Merck & Co./ Taiho Pharmaceutical)
5.4.1 Zolinza for Multiple Myeloma Treatment
5.4.2 Zolinza Revenue Forecast 2014-2024
5.5 Istodax: Second Epigenetic Drug by Celgene Co.
5.5.1 Istodax: Strong Revenue Growth 2010-2011
5.5.2 International Market Approvals to Drive Growth?
5.5.3 Istodax: Revenue Forecast 2014-2024
5.6 Epigenetic Therapy Market 2013: Rich Pipeline for HDAC Inhibitors
5.6.1 Beleodaq (TopoTarget/ Spectrum Pharmaceuticals): A Novel HDAC Inhibitor
5.6.2 Faridak (Novartis): Treatment for Velcade-Refractory Multiple Myeloma
5.6.3 Entinostat (Syndax Pharmaceuticals, Inc.): Breast and Lung Cancer
5.6.4 Resminostat (4SC/ Yakult Honsha Co.): Hepatocellular Carcinoma
5.6.5 Pracinostat (MEI Pharma): Treatment for MDS and AML
5.6.6 Mocetinostat: Initiatives of Mirati Therapeutics to Drive Development
5.6.7 Quisinostat (Janssen Pharmaceutica, NV/ NewVac LLC)
5.6.8 Rocilinostat (Acetylon Pharmaceuticals): One of Celgene’s Keen Interest
5.6.9 CHR-3396 (Chroma Therapeutics)
5.6.10 Givinostat (Italfarmaco): Chronic Myeloproliferative Neoplasms and Duchenne Muscular Dystrophy
5.6.11 Shape (TetraLogic Pharmaceuticals): The First Topical HDAC inhibitor for CTCL
5.6.12 FRM-0334 (Forum Pharmaceuticals Inc): Neurodegenerative Diseases
5.6.13 4SC-202: Second Epigenetic Drug by 4SC Has Potential for Wider Indications
5.6.14 Tefinostat (Chroma Therapeutics): Haematological Cancer
5.6.15 CDX10 (Celleron Therapeutics): Part of Personalised Cancer Treatment Trial
5.6.16 RG2833 (The Scripps Research Institute): Friedreich’s Ataxia
5.6.17 Abexinostat (Pharmacyclics)
5.7 New Discoveries in the Field of HDAC 2013
5.7.1 Chemogenic Approaches to Spatiotemporal Regulation of HDAC Activity
5.7.2 Novel Lysine Pathways and Acetylation-Independent Mechanisms of HDACs
5.7.3 HDAC Inhibitor: Treatment of Pathological Muscle Remodelling
5.7.4 Design of Class I Isoform Selective Inhibitors for Use in Metabolic Indications
5.7.5 Zinc Binding Groups Inhibit Class IIa HDAC and Alters Immune Responses
5.8 DNMT Inhibitor R&D Pipeline 2013
5.8.1 SGI-110 (Otsuka Pharmaceuticals): A Second Generation DNMT Inhibitor
5.8.2 FdCyd (National Cancer Institute): Solid Tumours
5.8.3 Hydralazine: Being Tested in 23 Clinical Trials
5.8.4 MG98 (Mirati Therapeutics)
5.8.5 CP-4200: A Second Generation Vidaza
5.8.6 RX3117 (Rexahn Pharmaceuticals)
5.9 Pipeline Treatments Targeting Other Epigenetic Enzymes 2013
5.9.1 EPZ-5676 (Epizyme Inc./ Celgene Co.): The First Clinical-Stage HMT Inhibitor
5.9.2 EPZ-5676 (Epizyme Inc./ Eisai): The Second Clinical-Stage HMT Inhibitor
5.9.3 ORY-1001(Roche): Orphan Drug Status in Early Stage AML
5.9.4 SP-2528 (Salarius Pharmaceuticals)
5.9.5 RVX-208 (Resverlogix): Advancing BET Protein Inhibitors
5.10 MiRNA Therapy Pipeline 2013
5.10.1 Miravirsen (Santaris Pharma A/S): The First miRNA Therapy to Enter Human Clinical Trial
5.10.2 MRX34 (Mirna Therapeutics)
5.10.3 Collaborations of Regulus Therapeutics with Big Pharma Players
5.11 Leading Epigenetic Therapy Manufacturers and Developers
5.11.1 Celgene: Market Leader in 2013
5.11.2 Eisai
5.11.3 Janssen-Cilag
5.11.4 Otsuka Pharmaceuticals
5.11.5 Merck & Co.
5.11.6 TopoTarget to Merge with BioAlliance Pharma SA
5.11.7 Syndax Pharmaceuticals
5.11.8 4SC
5.11.9 Curis: Focusing on Multi-Targeted Treatments
5.11.10 CellCentric: Collaborating with Big Pharma for Drug Development
5.11.11 Constellation Pharmaceuticals
5.11.12 EpiTherapeutics
5.11.13 Epizyme: Signed Multiple Collaboration Agreements with Big Pharma
5.11.14 IkerChem: HDAC and DNMT Inhibitors in Cancer and CNS Disorders
5.11.15 Karus Therapeutics: HDAC Inhibitors for Inflammatory Diseases and Cancer

6. Epigenetic Technologies: Markets 2014-2024
6.1 Epigenetic Technologies and Services Market 2014-2024
6.1.1 Should Epigenetic Discovery and Analysis Be Outsourced?
6.2 Next Generation Sequencing (NGS)
6.2.1 Higher Speed and Reduced Costs for Epigenetic Research
6.2.2 Are Current Bioinformatic Programmes a Setback?
6.2.3 Single Molecule Sequencing to Compete with NGS
6.3 The Future of Chromatin Immunoprecipitation
6.3.1 ChIP-Seq
6.4 Future Developments in Bisulphite Screening
6.4.1 Importance of Techniques to Distinguish 5hmC
6.5 High Throughput Screening
6.6 Leading Providers of Epigenetics Technologies 2013
6.6.1 Active Motif
6.6.2 Measurement Tools for Epigenetic Research by Agilent Technologies
6.6.3 Diagenode: Best –In-Class Methyl Binding Domain Based Kit
6.6.4 DiscoveRx
6.6.5 EMD Millipore
6.6.6 Epigenetek: Specialist in Epigenetic Technologies
6.6.7 Epiontis: Assessing Purity in Regenerative Medicine Products
6.6.8 Life Technologies: Reducing NGS Process Cost
6.6.9 Qiagen: Epigenetic Technologies and Diagnostics
6.6.10 Roche

7. Epigenetic Diagnostics Market 2014-2024
7.1 Development of the Epigenetic Diagnostics Market 2014-2024
7.1.1 LDTs vs. IVDs: Two Diagnostics Development Strategies
7.2 Epigenetic Diagnostics Market 2013
7.2.1 Epi proColon 2.0 (Epigenomics)
7.2.2 ColoVantage (Quest Diagnostics)
7.2.3 Septin9 LDT (ARUP Laboratories)
7.2.4 ColoSure (LabCorp)
7.2.5 ConfirmMDx for Prostate Cancer
7.2.6 Gene Methylation in Prostate Cancer (LabCorp)
7.2.7 Epi proLung (Epigenomics)
7.2.8 MGMT Gene Methylation Assay (LabCorp)
7.2.9 PredictMDx (MDxHealth): Brain Cancer
7.2.10 Bladder Cancer Testing with CertNDx (Physician’s Choice Laboratory Services)
7.3 Epigenetic Diagnostics R&D Pipeline 2013
7.3.1 The Future of Colorectal Cancer Testing Cologuard: Improved Sensitivity Orion Colorectal Cancer Risk Test (Orion Genomics)
7.3.2 Pipeline of Prognostic Tools for Prostate Cancer
7.3.3 Lung Cancer Lung Cancer Screening Test (Orion Genomics) ConfirmMDx and InformMDx (MDxHealth)
7.3.4 The Future of Bladder Cancer Testing Bladder Cancer Screening Test (Orion Genomics)
7.3.5 Other Cancer Tests Pipeline 2013 Pancreatic Cancer Prognostic Test (PrognosticDx Health)
7.4 Leading Epigenetic Diagnostic Developers 2013
7.4.1Epigenomics: Multiple Tests Marketed in the EU Positive Revenue Growth 2012-2013
7.4.2 Exact Sciences: Colorectal Cancer Screening
7.4.3 MDxHealth: Targeting the US Diagnostics Markets Strong Revenue Growth 2009-2013
7.4.4 Orion Genomics: More than 100 Markers Have Been Discovered
7.4.5 Physician’s Choice Laboratory Services (PCLS)
7.4.6 PrognosDx Health: Developing Epigenetic Prognostics

8. Research and Product Development Strategies in Epigenetics 2014
8.1 Epigenetics Therapies, Technologies and Diagnostics Market by Disease 2014-2024
8.2 Present and Future Epigenetic Research in Cancer
8.2.1 Twin Studies Reveal Epigenetic Biomarkers in Breast Cancer
8.2.2 Colorectal Cancer: More Than Two Biomarkers Established
8.2.3 Lung Cancer: Prognostic Markers
8.2.4 Prostate Cancer: The Need for Progression in Epigenetic Therapies
8.3 The Role of DNA Hypomethylation in Autoimmune Diseases
8.3.1 Lupus
8.3.2 Rheumatoid Arthritis as a Target for Drugs and Diagnostics Ignyta: Pioneer in Epigenetic Diagnostic for Rheumatoid Arthritis
8.3.3 Prevalence of Diabetes linked to Diet and Ageing
8.4 Neurodegenerative Diseases
8.4.1 Alzheimer’s Disease: Symptoms Improved with HDAC Inhibitors
8.4.2 Huntington’s Disease: Epigenetic Drugs in Clinical Development
8.5 Neurological Disorders
8.5.1 Drug Resistance in Schizophrenia
8.5.2 Hundreds of Genetic and Epigenetic Mutations linked to Autism
8.6 New Epigenetic Therapy Targets
8.6.1 BET Proteins Targeted by Multiple Therapeutic Areas
8.6.2 Importance of DNA Hydroxymethylation
8.6.3 Sirtuins: Undergoing Limited Research
8.6.4 Histone Methyltranferase Lysine Methyltranferase Domainex: Development of HMT Inhibitor Protein Arginine Methyltransferases: The Need for Improved Potency Lysine Demethylases: Potential Cancer Treatment Target

9. Epigenetic Therapies, Diagnostics and Related Technologies: Industry and Market Trends 2014-2024
9.1 Epigenetic Therapies, Technologies and Diagnostics: Strengths and Weaknesses 2014-2024
9.1.1 Understanding Epigenetic Markers and Mechanisms
9.1.2 Specificity of Marketed Epigenetic Therapies
9.2 Epigenetics Therapies, Technologies and Diagnostics Market Opportunities and Threats 2014-2024
9.2.1 The Important Role of Translational Research
9.2.2 Development of Companion Diagnostics in Conjunction with Therapies
9.2.3 Rich Therapeutic and Diagnostic Pipelines
9.2.4 Combination Therapy with Epigenetic Drugs Show Promise
9.2.5 Epigenetic Drugs to Succeed Drug Resistance
9.2.6 Therapy Target Scope besides HDAC and DNMT Inhibition
9.3 Epigenetics Therapies, Technologies and Diagnostics: STEP Analysis 2014-2024
9.4 Social Factors Affecting Epigenetic Product Development
9.4.1 The Influence of Environment
9.4.2 The Role of Epigenetics in Ageing and Diseases Increasing Prevalence of Global Disease to Drive Epigenetics Market Growth
9.4.3 Targeting Orphan Diseases and Patient Subpopulations
9.4.4 Use of Epigenetics in Personalised and Stratified Medicine
9.5 Advancing Epigenetic Technologies to Support Epigenetic Research
9.5.1 NGS: Improving the Quality of Epigenetic Research
9.5.2 Epigenetics to Help Drive Stem Cell Research Development
9.5.3 Complementary and Competing Forces Genomics Proteomics Metabolomics
9.6 Economic Factors
9.6.1 Recent Developments Helped Reduce Costs in Epigenetic Research
9.6.2 Importance of Big Pharma in Epigenetic Markets 2014-2024 Pfizer Novartis GSK: Part of Multiple Agreements in Epigenetics
9.6.3 Valuable Licensing Deals in Epigenetics
9.6.4 Epigenetic Business Models
9.7 Political Issues
9.7.1 Ethics in Epigenetic Research
9.7.2 Global Collaboration to Expedite Market Growth Structural Genome Consortium Roadmap Epigenomics Project (NIH) International Human Epigenome Consortium Blueprint Project

10. Research Interview
10.1 Interview with Dr Eric Marcotte, Strategic Lead, Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC)
10.1.1 Canadian Institute of Health Research: Interest in Epigenetics
10.1.2 Canadian Epigenetic Therapy Market
10.1.3 Prominent Epigenetic Therapeutic Areas in the Future
10.1.4 Promising New Epigenetic Therapy and Diagnostics
10.1.5 Future of Canadian Epigenetics Market
10.1.6 CIHR and JST Partnership Outcome

11. Conclusions from the Research and Analysis
11.1 Therapies Submarket Accounts for Most of the Epigenetic Market Revenues in 2013
11.2 Growth Expected in All Submarkets of the Epigenetic Market 2014-2024
11.2.1 Developed National Pharma Markets to Lead, 2014-2024
11.3 Many Opportunities Exist in the Epigenetics Industry and Market

List of Tables
Table 1.1 Global Epigenetics Market Forecast: Market Size ($m), AGR (%) and CAGR (%) by Region, 2013-2024
Table 2.1 Selected Enzymes Involved in Epigenetics
Table 2.2 Selected Treatments for MDS, 2013
Table 3.1 Epigenetic Therapies, Technologies and Diagnostics Sector: Global Market Size ($m) and Market Share (%), 2013
Table 3.2 Epigenetic Therapies, Technologies and Diagnostics: Market Size ($m), AGR (%) and CAGR (%) Forecast, 2013-2024
Table 3.3 Epigenetic Therapies, Technologies and Diagnostics: Submarket Shares (%), 2013-2024
Table 3.4 Epigenetic Therapies Submarket by Drug: Market Size ($m) and Market Share (%), 2013
Table 3.5 Epigenetic Therapies Submarket: Market Size ($m), AGR (%) and CAGR (%) Forecasts by Drug, 2013-2024
Table 3.6 Epigenetic Technologies Submarket: Global Market Size ($m) Forecast, 2013-2024
Table 3.7 Epigenetic Diagnostics Submarket: Global Market Size ($m) Forecast, 2013-2024
Table 4.1 Epigenetic Therapies, Technologies and Diagnostics: Market Size ($m) and Market Share (%) by Region, 2013
Table 4.2 Global Epigenetic Market Forecast: Market Size ($m), AGR (%) and CAGR (%) by Region, 2013-2024
Table 4.3 Epigenetic Therapies, Technologies and Diagnostics: Market Share (%) by Region, 2013-2024
Table 4.4 Epigenetic Therapies, Technologies and Diagnostics: US Market Size ($m) Forecast, 2013-2024
Table 4.5 Epigenetic Therapies, Technologies and Diagnostics: Canadian Market Size ($m) Forecast, 2013-2024
Table 4.6 Epigenetic Therapies, Technologies and Diagnostics: EU Market Size ($m) and Market Share (%) by Leading Country, 2013
Table 4.7 Selected Epigenetics Companies with Headquarters in the EU, 2013
Table 4.8 Epigenetic Therapies, Technologies and Diagnostics: EU Market Size ($m) Forecast, 2013-2024
Table 4.9 EU Epigenetics Therapies, Technologies and Diagnostics Market: Market Size ($m) Forecasts by Leading Country, 2013-2024
Table 4.10 Epigenetic Therapies, Technologies and Diagnostics: German Market Size ($m) Forecast, 2013-2024
Table 4.11 Epigenetic Therapies, Technologies and Diagnostics: UK Market Size ($m) Forecast, 2013-2024
Table 4.12 Epigenetic Therapies, Technologies and Diagnostics: Japanese Market Size ($m) Forecast, 2013-2024
Table 4.13 Epigenetic Therapies, Technologies and Diagnostics: BRIC Nations (Grouped) Market Size ($m) Forecast, 2013-2024
Table 5.1 Epigenetic Therapies Submarket: Submarket Shares (%) by Drug, 2013-2024
Table 5.2 Vidaza: Historical Revenue ($m), AGR (%) and CAGR (%), 2004-2013
Table 5.3 Vidaza: Revenue ($m) by Region, H2 2012-2013
Table 5.4 Celgene Sponsored Trials of Oral Vidaza (azacitidine), 2013
Table 5.5 Selected Late-Stage Clinical Trials of Vidaza (azacitidine), 2013
Table 5.6 Vidaza Revenue ($m) Forecast, AGR (%) and CAGR (%), 2013-2024
Table 5.7 Dacogen: Historical Revenue ($m), Royalty Revenue ($m), AGR (%) and CAGR (%), 2006-2012
Table 5.8 Late-Stage Clinical Trials of Dacogen (decitabine), 2013
Table 5.9 Dacogen Revenue ($m) Forecast, AGR (%) and CAGR (%), 2013-2024
Table 5.10 Multiple Myeloma Prevalence by Region, 2013
Table 5.11 Selected Late-Stage Clinical Trials of Zolinza (vorinostat), 2013
Table 5.12 Zolinza: Revenue ($m) Forecast, AGR (%) and CAGR (%), 2013-2024
Table 5.13 Istodax: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2013
Table 5.14 Phase III Clinical Trials of Istodax (romidepsin), 2013
Table 5.15 Istodax: Revenue ($m) Forecast, AGR (%) and CAGR (%), 2013-2024
Table 5.16 Selected HDAC Inhibitors in Development, 2013
Table 5.17 TopoTarget/ Spectrum Pharmaceuticals Sponsored Clinical Trials of Beleodaq (belinostat), 2013
Table 5.18 Beleodaq: Revenue ($m) Forecast, AGR (%) and CAGR (%), 2015-2024
Table 5.19 Clinical Trials of Faridak (panobinostat), 2013
Table 5.20 Faridak: Revenue ($m) Forecast, AGR (%) and CAGR (%), 2015-2024
Table 5.21 Clinical Trials of Entinostat in Breast Cancer and Lung Cancer, 2013
Table 5.22 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer and Multiple Myeloma, 2012
Table 5.23 Clinical Trials of Resminostat (4SC-201), 2013
Table 5.24 Clinical Trials of Pracinostat, 2013
Table 5.25 Clinical Trials of Rocilinostat (ACY-1215), 2013
Table 5.26 Clinical Trials of Givinostat (ITF2357), 2013
Table 5.27 Selected DNMT Inhibitors in Development, 2013
Table 5.28 Clinical Trials of SGI-110, 2013
Table 5.29 Clinical Trials of FdCyd (5-Fluoro-2’-deoxycytidine), 2013
Table 5.30 Selected Pipeline for Other Epigenetic Enzyme Inhibitors, 2013
Table 5.31 Selected MiRNA Therapy Pipeline, 2013
Table 5.32 CellCentric’s Research Institution Affiliations, 2012
Table 5.33 IkerChem Epigenetic Pipeline, 2013
Table 6.1 Fall in Average Cost ($m) of Sequencing the Human Genome, 2000-2013
Table 6.2 Advantages of Single Molecule Sequencing over Next Generation Sequencing, 2014
Table 6.3 Selected Producers of Single Molecule Sequencing Technologies, 2014
Table 6.4 Life Technologies: Revenues ($m) and AGR (%) by Sector, 2011-2012
Table 7.1 Marketed Epigenetic Colorectal Cancer Test Cost ($), Specificity (%) and Sensitivity (%) Comparison, 2013
Table 7.2 Epigenomics: Historical Revenue ($m), AGR (%) and CAGR (%), 2009-2013
Table 7.3 MDxHealth: Diagnostics Pipeline, 2013
Table 7.4 MDxHealth: Historical Revenue ($m) and CAGR (%) by Source, 2009-2013
Table 8.1 US Prevalence of Cancers Targeted by Epigenetic Therapies and Diagnostics, 2013
Table 9.1 Epigenetic Therapies, Technologies and Diagnostics Market: Strengths and Weaknesses, 2014
Table 9.2 Epigenetic Therapies, Technologies and Diagnostics Market: Opportunities and Threats, 2014-2024
Table 9.3 Epigenetic Therapies, Technologies and Diagnostics Market: STEP Analysis, 2014-2024
Table 9.4 Selected Licensing Deals for Epigenetic Therapies, 2011-2014
Table 9.5 Selected University Spin-Outs in the Epigenetics Industry, 1997-2011
Table 9.6 IHEC Member Organisations, 2013
Table 11.1 Epigenetic Market Size ($m), Market Share (%) and CAGR (%) by Submarket, 2013, 2018 and 2024
Table 11.2 Epigenetic Therapies, Technologies and Diagnostics Market Size ($m), Market Share (%) and CAGR (%) by Region, 2013, 2018 and 2024



★調査レポート[世界におけるエピジェネティクスの研究開発、治療薬、診断製品市場] ( Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024 / VISG409050) 販売に関する免責事項
[世界におけるエピジェネティクスの研究開発、治療薬、診断製品市場] ( Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024 / VISG409050) についてEメールでお問い合わせ